In a separate transaction on December 12, 2024, Tendler acquired 35,800 RSUs as part of DocGo's 2021 Stock Incentive Plan. These RSUs will vest in two equal annual installments, beginning on the first anniversary of the grant date. For deeper insights into insider transactions and comprehensive financial analysis, including 12 additional ProTips, visit InvestingPro. For deeper insights into insider transactions and comprehensive financial analysis, including 12 additional ProTips, visit InvestingPro.
In a separate transaction on December 12, 2024, Tendler acquired 35,800 RSUs as part of DocGo's 2021 Stock Incentive Plan. These RSUs will vest in two equal annual installments, beginning on the first anniversary of the grant date. For deeper insights into insider transactions and comprehensive financial analysis, including 12 additional ProTips, visit InvestingPro.
In a separate transaction on December 12, 2024, Tendler acquired 35,800 RSUs as part of DocGo's 2021 Stock Incentive Plan. These RSUs will vest in two equal annual installments, beginning on the first anniversary of the grant date.
In other recent news, DocGo Inc. reported a decline in their third-quarter revenue for 2024 by 26% to $138.7 million, primarily due to the cessation of migrant-related projects. However, the company demonstrated strong performance across customer verticals and a significant increase in care gap closure programs. CEO Lee Bienstock revised the revenue guidance for 2024 to range between $620 million and $630 million, with an adjusted EBITDA of $70 million to $75 million.
DocGo also announced the renewal of a contract with a major Tennessee healthcare system through its Ambulnz subsidiary, strengthening a six-year relationship and promising the delivery of efficient medical transport services. The company also expanded into Mississippi through its subsidiary, Cardiac RMS, and into North Texas through EMS Direct, reflecting its ongoing commitment to enhancing healthcare services.
These recent developments underline DocGo's focus on expanding its healthcare services and technology offerings. Analysts from InvestingPro have given the company a "GREAT" overall rating, indicating its strong financial health. As part of its leadership strategy, DocGo has welcomed Dr. Stephen Klasko as the new Chair of the Board. The company anticipates its cash flow from operations to be between $90 million and $100 million for the full year 2024.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.